Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5434257 | 0.93 | KDM4E (0.54) | MTNR1AMTNR1BTDP1KDM4EMAPT | |
| SCHEMBL1395803 | 0.92 | MTNR1A (0.54) | MTNR1AMTNR1BKDM4EHTR2AHTR2C | |
| SCHEMBL2259815 | 0.88 | MTNR1A (0.50) | MTNR1AMTNR1BKDM4EHTR2AHTR2C | |
| SCHEMBL3810010 | 0.82 | KMT2A (0.44) | MTNR1AMTNR1BTDP1KDM4EMAPT | |
| SCHEMBL3811645 | 0.82 | LMNA (0.49) | MTNR1AMTNR1BTDP1KDM4EMAPT | |
| SCHEMBL3814595 | 0.82 | KMT2A (0.44) | MTNR1AMTNR1BTDP1KDM4EMAPT | |
| SCHEMBL8039755 | 0.81 | HTR2A (0.49) | MTNR1AMTNR1BKDM4EHTR2AHTR2C | |
| SCHEMBL9746697 | 0.80 | HTR2A (0.51) | MTNR1AMTNR1BHTR2AHTR2CMEN1 | |
| SCHEMBL3814833 | 0.80 | KDM4E (0.43) | TDP1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL4129093 | 0.80 | KDM4E (0.48) | TDP1KDM4EMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756135-B1 | ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-08-12 | — | — | EP | disclosed |
| EP-1756135-B1 | ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-08-12 | — | — | EP | disclosed |
| US-7569550-B2 | 14 and 15 membered ring compounds | GLAXO GROUP LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| US-20090170791-A1 | MACROLONES | GLAXO SMITH KLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O A CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170791-A1 | MACROLONES | GLAXO SMITH KLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O A CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170791-A1 | MACROLONES | GLAXO SMITH KLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O A CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-7547679-B2 | Ether linked macrolides useful for the treatment of microbial infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2009-06-16 | — | — | US | disclosed |
| US-7547679-B2 | Ether linked macrolides useful for the treatment of microbial infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2009-06-16 | — | — | US | disclosed |
| US-7547679-B2 | Ether linked macrolides useful for the treatment of microbial infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2009-06-16 | — | — | US | disclosed |
| US-20090062218-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| EP-1879903-A1 | ETHER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2008-01-23 | — | — | EP | disclosed |
| US-20070293472-A1 | Novel 14 and 15 Membered Ring Compounds | GLAXO GROUP LIMITED (GB) | 2007-12-20 | — | — | US | disclosed |
| US-20070185117-A1 | Novel 14 and 15 membrered ring compounds | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1756134-A1 | CARBAMATE LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2007-02-28 | — | — | EP | disclosed |
| EP-1756135-A1 | ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006120541-A1 | ETHER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006120545-A1 | 4' AMINO LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2006-11-16 | — | — | WO | disclosed |
| US-20060258600-A1 | 14- or 15-Membered macrolides substituted at the 4'' position such as 4''-O-[2-(2-{2-[2-(3-Carboxy-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinolin-6-ylamino)-ethoxy]-ethoxy}-ethylamino)-ethyl]-azithromycin 11,12-cyclic carbonate; therapy or prophylaxis of systemic or topical microbial infections | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-11-16 | — | — | US | disclosed |
| WO-2005108412-A1 | ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108413-A1 | CARBAMATE LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185117-A1 | Novel 14 and 15 membrered ring compounds | CYP51A1, LSS, IL17A | MTNR1A 2797/4885MTNR1B 2479/4885TDP1 4343/4885 |
| US-20060258600-A1 | 14- or 15-Membered macrolides substituted at the 4'' position such as 4''-O-[2-(2-{2-[2-(3-Carboxy-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinolin-6-ylamino)-ethoxy]-ethoxy}-ethylamino)-ethyl]-azithromycin 11,12-cyclic carbonate; therapy or prophylaxis of systemic or topical microbial infections | IL17A, IL15, CASP14 | MTNR1A 3221/4885MTNR1B 3140/4885TDP1 2149/4885 |
| US-20070293472-A1 | Novel 14 and 15 Membered Ring Compounds | IL17A, CYP51A1, IL15 | MTNR1A 2884/4885MTNR1B 2400/4885TDP1 4228/4885 |
| US-20090062218-A1 | MACROLONE COMPOUNDS | CYP51A1, MRPL21, MYD88 | MTNR1A 3171/4885MTNR1B 1737/4885TDP1 3670/4885 |
| US-20090170791-A1 | MACROLONES | CYP51A1, MRPL21, LSS | MTNR1A 3387/4885MTNR1B 2690/4885TDP1 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.